130A Stock Overview
Veritas In Silico Inc. engages in the business of small molecule drug discovery and nucleic acid drug discovery targeting mRNA.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Veritas In Silico Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥1,870.00 |
| 52 Week High | JP¥3,475.00 |
| 52 Week Low | JP¥1,470.00 |
| Beta | 0 |
| 1 Month Change | 2.80% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -25.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| 130A | JP Life Sciences | JP Market | |
|---|---|---|---|
| 7D | 11.5% | 1.8% | 2.2% |
| 1Y | n/a | -34.2% | 28.4% |
Return vs Industry: Insufficient data to determine how 130A performed against the JP Life Sciences industry.
Return vs Market: Insufficient data to determine how 130A performed against the JP Market.
Price Volatility
| 130A volatility | |
|---|---|
| 130A Average Weekly Movement | 18.5% |
| Life Sciences Industry Average Movement | 6.4% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.1% |
| 10% least volatile stocks in JP Market | 2.3% |
Stable Share Price: 130A's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 130A's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Shingo Nakamura | www.veritasinsilico.com |
Veritas In Silico Inc. engages in the business of small molecule drug discovery and nucleic acid drug discovery targeting mRNA. The company was incorporated in 2016 and is based in Shinagawa, Japan.
Veritas In Silico Inc. Fundamentals Summary
| 130A fundamental statistics | |
|---|---|
| Market cap | JP¥11.91b |
| Earnings (TTM) | JP¥0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 130A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 130A income statement (TTM) | |
|---|---|
| Revenue | JP¥0 |
| Cost of Revenue | JP¥0 |
| Gross Profit | JP¥0 |
| Other Expenses | JP¥0 |
| Earnings | JP¥0 |
Last Reported Earnings
n/a
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 130A perform over the long term?
See historical performance and comparison